Journal of Contemporary Brachytherapy

Abstract

3/2021 vol. 13
Case report

Adjuvant high-dose-rate interstitial brachytherapy for malignant peripheral nerve sheath tumor of the foot: a case report

  1. Department of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy
  2. Division of Sarcoma and Melanoma, IEO European Institute of Oncology IRCCS, Milan, Italy
  3. Unit of Medical Physics, IEO European Institute of Oncology IRCCS, Milan, Italy
  4. Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy
  5. Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy
  6. University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy
J Contemp Brachytherapy 2021; 13, 3: 338–346
Online publish date: 2021/05/18
View full text
Soft tissue sarcomas of the foot are extremely rare and can therefore be misdiagnosed as benign diseases, and be prematurely removed with an unplanned excision. The standard treatment is a wide local excision with an addition of radiotherapy as an alternative to a radical resection (e.g., below-knee or foot amputation). We report on a patient with primary malignant peripheral nerve sheath tumor in the foot plantar soft tissue, who had no evidence of the disease and no severe late toxicity higher than grade 2, 40 months after receiving amputation of toes and adjuvant interstitial high-dose-rate brachytherapy (HDR-BT). To the best of our knowledge, only a few cases were treated with HDR-BT with this scenario. From our findings, HDR-BT could be a safe and quick treatment option for these types of lesions.
Share
without publication fees